Cargando…

2494. Real-World Use of Ibalizumab in Physician Office Infusion Centers (POICs)

BACKGROUND: Ibalizumab-uiyk (IBA) was recently approved for the treatment of multi-drug-resistant HIV-1 infection in patients (pts) failing other antiretroviral regimens. Clinical trial data demonstrated a decrease in HIV-1 viral load in 83% and 43% of patients (n = 40) receiving IBA for 2 and 25 we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prokesch, Richard C, Schroeder, Claudia P, Hardin, Thomas C, Van Anglen, Lucinda J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809768/ http://dx.doi.org/10.1093/ofid/ofz360.2172

Ejemplares similares

1016. Real-World Use of Omadacycline in Physician Office Infusion Centers (POICs)
por: Van Anglen, Lucinda J, et al.
Publicado: (2022)

2367. Infection Incidence and Utilization of Antimicrobials in Physician Office Infusion Centers (POICs)
por: Van Anglen, Lucinda J, et al.
Publicado: (2018)

597. The Impact of COVID-19 on Outpatient Intravenous Antimicrobial Therapy (OPAT) in Physician Office Infusion Centers (POICs)
por: Martin, Clifford P, et al.
Publicado: (2021)

2380. Healthcare Resource Utilization for High-Risk Patients Treated With Dalbavancin in Physician Office Infusion Centers (POICs)
por: Luu, Quyen, et al.
Publicado: (2018)

755 Comparison of Outpatient Antimicrobial Therapy (OPAT) in a Physician Office Infusion Center (POIC) vs Traditional Home Health Care (HHC)
por: Prokesch, Richard C., et al.
Publicado: (2014)

763 Low Hospital Admission Rates Following Physician Office Infusion Center (POIC)-Based Outpatient Treatment with Intravenous Antibiotics (IVABs)
por: Alvarado, Fernando S., et al.
Publicado: (2014)

313. Outpatient Treatment and Recurrence of Prosthetic Joint Infection (PJI) in Infectious Disease (ID) Physician Office Infusion Centers (POICs): A 2-Year Retrospective Multicenter Analysis
por: Metzger, Brian S, et al.
Publicado: (2018)

1625. Real-World Outpatient Utilization of Ceftolozane/Tazobactam in Physician Office Infusion Centers (OICs)
por: Van Anglen, Lucinda J, et al.
Publicado: (2020)

750. Serious Bacterial Infections: Successful Outpatient Management by Infectious Disease Physicians in Office Infusion Centers
por: Adams, John S, et al.
Publicado: (2019)

598. A 3-Year Evaluation of Antibiotic Resistance Patterns in Gram-Negative Genitourinary Tract Infections Treated in Outpatient Infusion Centers (POICs)
por: Hengel, Richard L, et al.
Publicado: (2021)

2081. Low 30-Day Hospital Readmission Rates in Medicare Patients Receiving Outpatient Parenteral Antimicrobial Therapy (OPAT) in Physician Office Infusion Centers
por: Luu, Quyen, et al.
Publicado: (2019)

1327. Vancomycin Dosing by AUC(24)/MIC in Comparison to Traditional Trough Dosing in Office Infusion Centers (OICs)
por: Luu, Quyen, et al.
Publicado: (2020)

614. Long-Acting Lipoglycopeptides for the Treatment of Bone and Joint Infections and Bacteremia in Infectious Disease Outpatient Infusion Clinics
por: Metzger, Brian S, et al.
Publicado: (2020)

A Real-world Multicenter Outpatient Experience of Ceftolozane/Tazobactam
por: Van Anglen, Lucinda J, et al.
Publicado: (2023)

2493. Real-World Utilization of Ibalizumab (IBA) Without an Optimized Background Regimen (OBT)
por: Bouchard, Jeannette, et al.
Publicado: (2019)

Ibalizumab: First Global Approval
por: Markham, Anthony
Publicado: (2018)

Correction to: Ibalizumab: First Global Approval
por: Markham, Anthony
Publicado: (2018)

1854. Effective Antimicrobial Stewardship for Outpatient Parenteral Antimicrobial Therapy (OPAT): Nationwide Experience in Infectious Disease Physician Infusion Centers
por: Nathan, Ramesh V, et al.
Publicado: (2018)

501. Evaluation of Bezlotoxumab in Prevention of Recurrent C. difficile Infection: A Multicenter Single-Arm Study in Outpatient Infusion Centers
por: Hengel, Richard L, et al.
Publicado: (2018)

Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy
por: Iacob, Simona A., et al.
Publicado: (2017)

544. Pharmacokinetic Profile of Ibalizumab From a Phase 3 Trial
por: Kumar, Princy N, et al.
Publicado: (2018)

Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc
por: Rose, Ronald, et al.
Publicado: (2022)

Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study
por: Hengel, Richard L, et al.
Publicado: (2020)

Reactivation of Hepatitis B After Ibalizumab Therapy for Multidrug-Resistant Human Immunodeficiency Virus
por: Kaplan, Alyson, et al.
Publicado: (2021)

2494. Influenza B Hospitalizations Are Associated With Mortality in Children, FluSurv-NET, 2011–2017
por: Garg, Shikha, et al.
Publicado: (2018)

The Pan-Sirtuin Inhibitor MC2494 Regulates Mitochondrial Function in a Leukemia Cell Line
por: Carafa, Vincenzo, et al.
Publicado: (2020)

787. Evaluation of Clostridioides difficile Environmental Contamination Surrounding C. difficile Patients vs. non-C. difficile Patients in Outpatient Infusion Centers
por: Garey, Kevin W, et al.
Publicado: (2020)

1027. Long-Term Efficacy, Safety, and Durability of Ibalizumab-Based Regimens in Subgroup of TMB-202 Participants
por: Towner, William, et al.
Publicado: (2020)

2382. Recurrent Clostridioides difficile Infection (CDI) Worsens Anxiety-Related Patient-Reported Quality of Life
por: Garey, Kevin W, et al.
Publicado: (2019)

Real-World Experience With Acute Infusion Reactions to Ustekinumab at 2 Large Tertiary Care Centers
por: Spencer, Elizabeth A, et al.
Publicado: (2020)

Forty-eight-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1
por: Emu, Brinda, et al.
Publicado: (2017)

661. Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311)
por: Emu, Brinda, et al.
Publicado: (2019)

1008. Disease Severity Impact on Long-Term Virologic Response to Ibalizumab in Expanded Access Protocol (TMB-311)
por: Kumar, Princy, et al.
Publicado: (2020)

2494 Selectives: Implementing self-directed collaborative selectives as part of a curriculum for pre-health care professional students
por: Corsino, Leonor, et al.
Publicado: (2018)

610. Low Rates of Acute Kidney Injury (AKI) in Outpatient Vancomycin Managed by Pharmacists using Precision Dosing Software
por: Schroeder, Claudia P, et al.
Publicado: (2022)

Identification of Restriction-Modification Systems of Bifidobacterium animalis subsp. lactis CNCM I-2494 by SMRT Sequencing and Associated Methylome Analysis
por: O′Connell Motherway, Mary, et al.
Publicado: (2014)

Bifidobacterium animalis ssp. lactis CNCM-I2494 Restores Gut Barrier Permeability in Chronically Low-Grade Inflamed Mice
por: Martín, Rebeca, et al.
Publicado: (2016)

2494: Have interdisciplinary collaborations increased over the last 10 years at Johns Hopkins University? Results of a pilot study
por: Weston, Christine M., et al.
Publicado: (2018)

Efficacy, Pharmacokinetics, and Safety Over 48 Weeks With Ibalizumab-Based Therapy in Treatment-Experienced Adults Infected With HIV-1: A Phase 2a Study
por: Gathe, Joseph C., et al.
Publicado: (2021)

Medical licensing examination (uigwa) and the world of the physician officers (uigwan) in Korea’s Joseon Dynasty
por: Lee, Nam Hee
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_m7o0fb64iclbjsd5m1rk0ijn7i